Does UnitedHealthcare Cover Trelegy?
The verdict
Covered on most plans
UnitedHealthcare covers Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) across commercial and Medicare Part D lines through its PBM OptumRx. Trelegy is brand-only with no generic, so coverage does not depend on generic substitution. The typical friction on UHC is OptumRx step-therapy logic, which commonly requires documentation of a simpler inhaler tried before approving triple-combination therapy. The 2026 $2,100 Medicare Part D out-of-pocket cap applies.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with UnitedHealthcare using your member ID.
Key facts
UnitedHealthcare administers its pharmacy benefit through OptumRx, which commonly applies step-therapy requirements for brand triple-therapy inhalers like Trelegy across commercial and Part D plans.
OptumRx formulary policies; UHC plan documents
Trelegy Ellipta is brand-only — no FDA-approved generic exists as of 2026 — making step therapy, not generic substitution, the primary coverage variable at UHC.
FDA drug labeling, Trelegy Ellipta
The 2026 Medicare Part D $2,100 out-of-pocket cap limits annual drug spending for all Medicare Part D enrollees including those on UHC plans.
CMS, Medicare Part D 2026 benefit parameters
Medicare vs. commercial coverage
Whether UnitedHealthcare covers Trelegy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
UnitedHealthcare Medicare Part D and Medicare Advantage plans cover Trelegy Ellipta through OptumRx as a brand maintenance inhaler for COPD and asthma. No generic exists, so there is no generic-substitution tier edit. OptumRx formularies on Part D plans commonly apply step therapy requiring documentation that a single- or dual-agent inhaler was tried first. The 2026 Medicare Part D $2,100 out-of-pocket cap applies. Verify PA and step-therapy requirements on the specific UHC Medicare plan formulary or at myuhc.com.
Commercial / Employer
Group & marketplace plans
UnitedHealthcare commercial/employer and ACA/individual plans cover Trelegy Ellipta through OptumRx as a brand maintenance inhaler, subject to tier and step-therapy requirements. OptumRx's commercial formularies also commonly require a trial of a simpler inhaler before approving triple-therapy brands. UHC Community Plan (Medicaid) covers Trelegy per state PDL, with prior authorization and step therapy common for a brand-only triple-therapy inhaler. Across all lines, UHC administers coverage through OptumRx, providing a more uniform UM pattern than federation-based insurers. Verify on the UHC/OptumRx drug lookup.
The 3 boxes you must tick to get approved
Commercial plans that will consider Trelegy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Trelegy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$802–$918 per inhaler (30-day supply)
List price with no coverage — before any manufacturer savings card.
With coverage
Varies by UHC/OptumRx plan tier — confirm on the UHC/OptumRx drug lookup. Medicare Part D cost-share subject to the 2026 $2,100 out-of-pocket cap.
Typical monthly copay once prior authorization is approved.
Bridge program
GSK (Trelegy manufacturer) offers the myGSK Assistance Program for eligible uninsured and underinsured patients. Verify eligibility at gsk.com.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. No generic alternative exists for Trelegy. Actual cost-share depends on plan tier, deductible status, and pharmacy. Verify on the OptumRx formulary at myuhc.com or call UHC member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Use the UHC/OptumRx drug lookup
Log in to myuhc.com or the UHC mobile app and use the 'Find a Drug' or formulary tool. Enter 'Trelegy Ellipta,' select your specific plan, and review tier, prior authorization status, and step-therapy requirements administered by OptumRx.
- 2
Call UHC member services
Call the number on the back of your UHC member ID card and ask: Is Trelegy Ellipta on my OptumRx formulary? Is step therapy or prior authorization required? What is my expected cost-share for a 30-day supply?
- 3
Ask your prescriber to submit a PA or step-therapy exception
If your UHC/OptumRx plan requires step-therapy documentation, your prescriber can submit clinical notes confirming COPD or asthma diagnosis and prior inhaler history through the OptumRx PA portal. If prior step-therapy requirements were already met, a step-therapy exception may accelerate approval.
Options if UnitedHealthcare won't cover Trelegy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Anoro Ellipta (umeclidinium/vilanterol)
Dual-agent LABA/LAMA without an ICS; may be on a lower OptumRx tier where step therapy is the initial pathway before triple therapy is approved.
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol)
Another brand triple-therapy COPD inhaler; compare OptumRx tier placement with Trelegy on your specific UHC plan before switching.
Generic budesonide-formoterol (ICS/LABA)
OptumRx-preferred dual-agent generic for asthma/COPD maintenance; often placed at a lower tier than Trelegy and may serve as the step-therapy option on UHC plans.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
OptumRx, UHC's PBM, commonly applies step-therapy requirements on brand triple-therapy inhalers like Trelegy. Step therapy requires documentation that the patient tried a simpler inhaler first. Because Trelegy is brand-only with no generic, the step is not about generic substitution — it is about demonstrating that triple combination therapy is clinically appropriate. If your COPD is documented and a simpler inhaler failed, the PA typically clears. Verify step-therapy requirements on your specific UHC/OptumRx plan formulary.
No. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is brand-only — no FDA-approved generic exists as of 2026. This differs from Symbicort, where OptumRx strongly prefers the generic budesonide/formoterol and often moves brand Symbicort to non-preferred. For Trelegy, OptumRx cannot substitute a generic, so the UHC coverage question is whether step therapy and PA requirements are met — not whether to use the generic.
Yes. The 2026 Medicare Part D $2,100 beneficiary out-of-pocket cap applies to covered drugs including Trelegy on UHC Medicare Part D and Medicare Advantage plans administered through OptumRx. Once you reach the cap, you pay $0 for covered Part D drugs for the rest of the year. This significantly limits exposure given Trelegy's cash price of $802–$918 per inhaler. Cost-share before the cap depends on your UHC plan's OptumRx tier for Trelegy.
The two inhalers have opposite coverage logic at UHC/OptumRx. Symbicort has a widely available generic (budesonide/formoterol) that OptumRx prefers at a lower tier — brand Symbicort is frequently non-preferred or not covered on Part D. Trelegy is brand-only with no generic, so OptumRx cannot apply a generic-first policy; instead, the friction is step therapy requiring a simpler inhaler trial. Same PBM, structurally different coverage mechanisms.
Trelegy was selected by CMS for Medicare drug price negotiation in a later cohort — not the first 10 drugs whose negotiated prices took effect in 2026. A government-negotiated Trelegy price was not in effect in 2026 for UHC Medicare plans. Do not assume any negotiated-price savings. Verify the current effective year against the CMS selected-drug list before expecting a reduction beyond the standard 2026 Part D OOP cap protections.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with UnitedHealthcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.